Cowen analyst Boris Peaker raised the firm’s price target on Merck to $120 from $108 and keeps a Market Perform rating on the shares. The analyst said the company’s earnings per share growth appears just above the industry average through 2027 and although he raised his near-term sales forecast, he lowered them longer-term.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- 2 Defensive Stocks to Protect Your Portfolio Through 2023
- MRK Slips Despite New Chinese Approval
- FDA determines Evaxion Biotech can proceed with Phase 2B trial of EVX-01
- Merck’s Covid treatment gets conditional approval in China, Reuters reports
- Cantor calls Merck top large cap pharma pick, names 8 SMID cap top picks